Atomoxetine for the Treatment of Cannabis Dependence

Status Completed

Clinical Trial Summary

The purpose of this small open-label trial is to evaluate the feasibility of recruiting cannabis dependent patients for treatment with Atomoxetine and MIT. The clinical data to date on Atomoxetine has been limited to children and adults with attention deficit disorder without co-morbid substance dependence. However, one study estimated that adults with attention deficit disorder have rates of drug abuse three to four times higher than controls (Mannuzza S 1998). The study also reported that cannabis and cocaine are most frequently abused in this population.

Clinical Trial Description

This is a Phase 2 open-label study. We will recruit 10 cannabis dependent subjects and treat them with the combination of Atomoxetine and MIT to reduce their consumption of cannabis. Subjects will be 10 men and women with current DSM-IV diagnosis of cannabis dependence. All patients will receive Atomoxetine and four sessions of MIT. The study length for each patient will be one week for baseline screening and starting medication. This is followed by 8 weeks of medication and an end of study visit one week after completing medications.

The PI will review all information collected regarding the subject's eligibility for the study. The subject will return approximately four days later, and if the PI finds the subject suitable for the study, the subject will begin taking study medication. This visit is referred to as visit 2. During visit 2, the PI will monitor the subject for concomitant medications and adverse events. The research technician will collect Vital Signs, Weight, BAL, the TLFB, a Urine Tox Screen and THC/CR ratio. Both visits 1 and 2 will be conducted within the first week of the study. Starting at visit 2, subjects will take one 25mg capsule of Atomoxetine orally for seven days. Beginning at visit 3, subjects will increase the dose to 40mg per day for 3 days, followed by 80mg (two 40mg capsules concurrently) for the other four days of the second week. Beginning with week 3, subjects will take two 40mg capsules (80mg total) every day of the week for 6 weeks. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00167297
Study type	Interventional
Source	National Institute on Drug Abuse (NIDA)
Contact
Status	Completed
Phase	Phase 2
Start date	November 2004
Completion date	July 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01005810` - A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana	Phase 2
Completed	`NCT00114439` - Lithium Cannabis Withdrawal Study	Phase 2
Completed	`NCT00350285` - The Teen Marijuana Check-Up	Phase 2
Completed	`NCT01618656` - Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal	Phase 2
Completed	`NCT01153490` - Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine	Phase 4
Completed	`NCT02946489` - Facilitating the Behavioral Treatment of Cannabis Use Disorder	Phase 1
Completed	`NCT02088177` - Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence	Phase 1/Phase 2
Not yet recruiting	`NCT01565174` - The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis	N/A
Completed	`NCT01697709` - Quetiapine Pharmacotherapy for Cannabis Dependence	Phase 2
Recruiting	`NCT04721353` - Reducing Cannabis Overuse With Prazosin	Phase 4
Completed	`NCT01603992` - Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
Terminated	`NCT01598896` - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia	Phase 2/Phase 3
Completed	`NCT01611948` - Treatment for Cannabis Withdrawal and Dependence	Phase 2
Recruiting	`NCT03221231` - N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms	Phase 4
Not yet recruiting	`NCT03366909` - Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness	N/A
Completed	`NCT01639872` - Clozapine for Cannabis Use in Schizophrenia	Phase 4
Not yet recruiting	`NCT06334016` - Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream	Early Phase 1
Completed	`NCT01793961` - Effects of Chronic Intake of Cannabis on Contrast Sensitivity	N/A
Completed	`NCT01747850` - Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence	Phase 2
Completed	`NCT01834794` - Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.